FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 358:2433-2446 June 5, 2008 Number 23 Next

	Full Text PDF PDA Full Text PowerPoint Slide Set CME Exam Editorial by Ingelfinger, J. R. Letters Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear PubMed Citation

ABSTRACT

Background Diabetic nephropathy is the leading cause of end-stage renal disease in developed countries. We evaluated the renoprotective effects of dual blockade of the renin–angiotensin–aldosterone system by adding treatment with aliskiren, an oral direct renin inhibitor, to treatment with the maximal recommended dose of losartan (100 mg daily) and optimal antihypertensive therapy in patients who had hypertension and type 2 diabetes with nephropathy.

Methods We enrolled 599 patients in this multinational, randomized, double-blind study. After a 3-month, open-label, run-in period during which patients received 100 mg of losartan daily, patients were randomly assigned to receive 6 months of treatment with aliskiren (150 mg daily for 3 months, followed by an increase in dosage to 300 mg daily for another 3 months) or placebo, in addition to losartan. The primary outcome was a reduction in the ratio of albumin to creatinine, as measured in an early-morning urine sample, at 6 months.

Results The baseline characteristics of the two groups were similar. Treatment with 300 mg of aliskiren daily, as compared with placebo, reduced the mean urinary albumin-to-creatinine ratio by 20% (95% confidence interval, 9 to 30; P<0.001), with a reduction of 50% or more in 24.7% of the patients who received aliskiren as compared with 12.5% of those who received placebo (P<0.001). A small difference in blood pressure was seen between the treatment groups by the end of the study period (systolic, 2 mm Hg lower [P=0.07] and diastolic, 1 mm Hg lower [P=0.08] in the aliskiren group). The total numbers of adverse and serious adverse events were similar in the groups.

Conclusions Aliskiren may have renoprotective effects that are independent of its blood-pressure–lowering effect in patients with hypertension, type 2 diabetes, and nephropathy who are receiving the recommended renoprotective treatment. (ClinicalTrials.gov number, NCT00097955 [ClinicalTrials.gov] .)

Source Information

From the Department of Medical Endocrinology, Rigshospitalet, Copenhagen (H.-H.P.); the Faculty of Health Science, Aarhus University, Aarhus, Denmark (H.-H.P.); Steno Diabetes Center, Gentofte, Denmark (F.P.); Vanderbilt University School of Medicine, Nashville (J.B.L.); Rush University Medical Center, Chicago (E.J.L.); and Brigham and Women's Hospital and Harvard Medical School, Boston (N.K.H.).

Address reprint requests to Dr. Parving at the Department of Medical Endocrinology, Rigshospitalet, University Hospital of Copenhagen, Blegdamsvej 9, DK-2100 Copenhagen Ø, Denmark, or at hhparving{at}dadlnet.dk.

Full Text of this Article

Related Letters:

Aliskiren Combined with Losartan in Diabetes and Nephropathy
Panesar M., Damodar A., Lindner T., Anderson S., Komers R., Kamoi K., Parving H.-H., Persson F.
Extract | Full Text | PDF  
N Engl J Med 2008; 359:1068-1070, Sep 4, 2008. Correspondence

This article has been cited by other articles:

• Messerli, F. H. (2009). Reply. J Am Coll Cardiol 54: 279-280 [Full Text]  
• Mauer, M., Zinman, B., Gardiner, R., Suissa, S., Sinaiko, A., Strand, T., Drummond, K., Donnelly, S., Goodyer, P., Gubler, M. C., Klein, R. (2009). Renal and Retinal Effects of Enalapril and Losartan in Type 1 Diabetes. NEJM 361: 40-51 [Abstract] [Full Text]  
• Sever, P. S, Gradman, A. H, Azizi, M. (2009). Managing cardiovascular and renal risk: the potential of direct renin inhibition. Journal of Renin-Angiotensin-Aldosterone System 10: 65-76 [Abstract]  
• Parving, H.-H., Brenner, B. M., McMurray, John. J. V., de Zeeuw, D., Haffner, S. M., Solomon, S. D., Chaturvedi, N., Ghadanfar, M., Weissbach, N., Xiang, Z., Armbrecht, J., Pfeffer, M. A. (2009). Aliskiren Trial in Type 2 Diabetes Using Cardio-Renal Endpoints (ALTITUDE): rationale and study design. Nephrol Dial Transplant 24: 1663-1671 [Abstract] [Full Text]  
• Nuzum, D. S., Merz, T. (2009). Macrovascular Complications of Diabetes Mellitus. Journal of Pharmacy Practice 22: 135-148 [Abstract]  
• Berl, T. (2009). Review: Renal protection by inhibition of the renin-angiotensin-aldosterone system. Journal of Renin-Angiotensin-Aldosterone System 10: 1-8 [Abstract]  
• Wenzel, R. R., Littke, T., Kuranoff, S., Jurgens, C., Bruck, H., Ritz, E., Philipp, T., Mitchell, A., for the SPP301 (Avosentan) Endothelin Antagonist E, (2009). Avosentan Reduces Albumin Excretion in Diabetics with Macroalbuminuria. J. Am. Soc. Nephrol. 20: 655-664 [Abstract] [Full Text]  
• Messerli, F. H. (2009). The sudden demise of dual renin-angiotensin system blockade or the soft science of the surrogate end point.. J Am Coll Cardiol 53: 468-470 [Abstract] [Full Text]  
• Solomon, S. D., Appelbaum, E., Manning, W. J., Verma, A., Berglund, T., Lukashevich, V., Cherif Papst, C., Smith, B. A., Dahlof, B., for the Aliskiren in Left Ventricular Hypertrophy, (2009). Effect of the Direct Renin Inhibitor Aliskiren, the Angiotensin Receptor Blocker Losartan, or Both on Left Ventricular Mass in Patients With Hypertension and Left Ventricular Hypertrophy. Circulation 119: 530-537 [Abstract] [Full Text]  
• Schernthaner, G. (2009). Kidney disease in diabetology: lessons from 2008. Nephrol Dial Transplant 24: 396-399 [Full Text]  
• American Diabetes Association, (2009). Standards of Medical Care in Diabetes--2009. Diabetes Care 32: S13-S61 [Full Text]  
• Saran, A. M., DuBose, T. D. Jr (2008). Cardiovascular disease in chronic kidney disease. Ther Adv Cardiovasc Dis 2: 425-434 [Abstract]  
• Perlini, S., Salinaro, F., Fonte, M. L. (2008). Direct Renin Inhibition: Another Weapon to Modulate the Renin-Angiotensin System in Postinfarction Remodeling?. Hypertension 52: 1019-1021 [Full Text]  
• Wright, J., Vardhan, A. (2008). Review: The problem of diabetic nephropathy and practical prevention of its progression. British Journal of Diabetes & Vascular Disease 8: 272-277 [Abstract]  
• (2008). {blacktriangledown}Aliskiren for hypertension in adults. DTB 46: 73-76 [Abstract] [Full Text]  
• SCHREIBER, M. J. JR, (2008). Preventing renal disease progression: Can complete renin-angiotensin-aldosterone blockade work?. Cleveland Clinic Journal of Medicine 75: 699-704 [Full Text]  
• Panesar, M., Damodar, A., Lindner, T., Anderson, S., Komers, R., Kamoi, K., Parving, H.-H., Persson, F. (2008). Aliskiren combined with losartan in diabetes and nephropathy.. NEJM 359: 1068-1069 [Full Text]  
• Kopple, J. D (2008). Do low-protein diets retard the loss of kidney function in patients with diabetic nephropathy?. Am. J. Clin. Nutr. 88: 593-594 [Full Text]  
• Ogihara, T., Rakugi, H. (2008). Which strategy in inhibition of the renin-angiotensin system is the most efficient for heart failure?. Journal of Renin-Angiotensin-Aldosterone System 9: 184-185  
• Verma, S., Gupta, M. K. (2008). Aliskiren Improves Nitric Oxide Bioavailability and Limits Atherosclerosis. Hypertension 52: 467-469 [Full Text]  
• Brown, M. J. (2008). Aliskiren. Circulation 118: 773-784 [Abstract] [Full Text]  
• Triplitt, C., Alvarez, C. A. (2008). Best Practices for Lowering the Risk of Cardiovascular Disease in Diabetes. Diabetes Spectr. 21: 177-189 [Abstract] [Full Text]  
• Ingelfinger, J. R. (2008). Aliskiren and Dual Therapy in Type 2 Diabetes Mellitus. NEJM 358: 2503-2505 [Full Text]  
• (2008). Beyond Blood Pressure Control: Targeting Proteinuria with Renin-Angiotensin-Aldosterone Inhibitors. Journal Watch Cardiology 2008: 1-1 [Full Text]  
• (2008). Aliskiren to Reduce Proteinuria in Diabetic Nephropathy. JWatch General 2008: 1-1 [Full Text]  
• Ruilope, L. M (2008). Renin Academy in Focus: Renin Academy presence at major congresses. Journal of Renin-Angiotensin-Aldosterone System 9: 123-123